English
Regional settings| Spread | 0.11 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
Information_provided_by_capital
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 14.66 |
| Open | 14.68 |
| 1-Year Change | 21.72% |
| Day's Range | 14.67 - 14.7 |
Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is entitled to receive contingent milestone payments related to its sale of ONIVYDE to Ipsen S.A. ONIVYDE is approved by the Unites States Food and Drug Administration (FDA) in combination with fluorouracil (5-FU) and leucovorin (LV) for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. The Company does not have any ongoing research or development activities and is seeking potential acquirers for its remaining preclinical and clinical assets.
BRIEF: For the nine months ended 30 September 2021, Merrimack Pharmaceuticals Inc revenues was not reported. Net loss increased 3% to $2M. Higher net loss reflects Gain on sale of assets decrease of 93% to $144K (income), Interest income decrease of 61% to $19K (income), Other income (expense), net decrease from $18K (income) to $0K. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.14 to -$0.15.
Common Stock $0.01 Par, 02/12, 200M auth., 94,756,679 issd. Insiders own 9.59%. IPO:TBA
